Drugs Made In America Acquisition Corp. (NASDAQ:DMAA) Sees Significant Decrease in Short Interest

Drugs Made In America Acquisition Corp. (NASDAQ:DMAA) was the recipient of a large drop in short interest in the month of April. As of April 30th, there was short interest totaling 103,808 shares, a drop of 92.9% from the April 15th total of 1,465,993 shares. Approximately 0.3% of the shares of the stock are short sold. Based on an average daily trading volume, of 163,128 shares, the short-interest ratio is currently 0.6 days.

Hedge Funds Weigh In On Drugs Made In America Acquisition

Several large investors have recently bought and sold shares of the stock. Wolverine Asset Management LLC increased its stake in Drugs Made In America Acquisition by 4.7% during the 4th quarter. Wolverine Asset Management LLC now owns 1,307,468 shares of the company’s stock valued at $13,564,000 after buying an additional 58,340 shares during the period. Mercuria Capital Strategies LLC acquired a new position in Drugs Made In America Acquisition during the 4th quarter valued at about $7,511,000. Boothbay Fund Management LLC acquired a new position in Drugs Made In America Acquisition during the 2nd quarter valued at about $5,814,000. Radcliffe Capital Management L.P. increased its stake in Drugs Made In America Acquisition by 3.5% during the 4th quarter. Radcliffe Capital Management L.P. now owns 546,808 shares of the company’s stock valued at $5,673,000 after buying an additional 18,708 shares during the period. Finally, Rivernorth Capital Management LLC increased its stake in Drugs Made In America Acquisition by 31.4% during the 4th quarter. Rivernorth Capital Management LLC now owns 417,998 shares of the company’s stock valued at $4,335,000 after buying an additional 100,000 shares during the period.

Drugs Made In America Acquisition Stock Performance

Drugs Made In America Acquisition stock remained flat at $10.60 during trading hours on Tuesday. 450 shares of the company’s stock traded hands, compared to its average volume of 130,255. The firm’s fifty day moving average price is $10.51 and its 200-day moving average price is $10.42. Drugs Made In America Acquisition has a 52-week low of $10.10 and a 52-week high of $10.60.

About Drugs Made In America Acquisition

Drugs Made In America Acquisition Corp (NASDAQ: DMAA) is a special purpose acquisition company incorporated in Delaware with the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The company’s stated focus is on identifying and acquiring one or more operating businesses in the U.S. pharmaceutical sector, particularly those involved in the domestic manufacturing of approved drugs, active pharmaceutical ingredients or related contract development and manufacturing services.

Operating as a blank‐check vehicle, Drugs Made In America Acquisition holds its funds in a trust account pending the completion of an initial business combination.